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Summary
Background—Reoperation rates are high after surgery for hip fractures. We investigated the
effect of a sliding hip screw versus cancellous screws on the risk of reoperation and other key
outcomes.
Methods—For this international, multicentre, allocation concealed randomised controlled trial,
we enrolled patients aged 50 years or older with a low-energy hip fracture requiring fracture
fixation from 81 clinical centres in eight countries. Patients were assigned by minimisation with a
centralised computer system to receive a single large-diameter screw with a side-plate (sliding hip
screw) or the present standard of care, multiple small-diameter cancellous screws. Surgeons and
patients were not blinded but the data analyst, while doing the analyses, remained blinded to
treatment groups. The primary outcome was hip reoperation within 24 months after initial surgery
to promote fracture healing, relieve pain, treat infection, or improve function. Analyses followed
the intention-to-treat principle. This study was registered with ClinicalTrials.gov, number
NCT00761813.
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Findings—Between March 3, 2008, and March 31, 2014, we randomly assigned 1108 patients to
receive a sliding hip screw (n=557) or cancellous screws (n=551). Reoperations within 24 months
did not differ by type of surgical fixation in those included in the primary analysis: 107 (20%) of
542 patients in the sliding hip screw group versus 117 (22%) of 537 patients in the cancellous
screws group (hazard ratio [HR] 0.83, 95% CI 0.63–1.09; p=0.18). Avascular necrosis was more
common in the sliding hip screw group than in the cancellous screws group (50 patients [9%] vs
28 patients [5%]; HR 1.91, 1.06–3.44; p=0.0319). However, no significant difference was found
between the number of medically related adverse events between groups (p=0.82; appendix); these
events included pulmonary embolism (two patients [<1%] vs four [1%] patients; p=0.41) and
sepsis (seven [1%] vs six [1%]; p=0.79).
Interpretation—In terms of reoperation rates the sliding hip screw shows no advantage, but
some groups of patients (smokers and those with displaced or base of neck fractures) might do
better with a sliding hip screw than with cancellous screws.
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Funding—National Institutes of Health, Canadian Institutes of Health Research, Stichting
NutsOhra, Netherlands Organisation for Health Research and Development, Physicians’ Services
Incorporated.

Introduction
Worldwide, 4.5 million people per year become disabled after sustaining a hip fracture, with
the number living with disability due to hip fracture expected to increase to 21 million in the
next 40 years.1,2 Despite surgical intervention, the need for reoperation remains high (10.0–
48.8%), has remained largely unchanged in the past 30 years,3,4 and is associated with
substantial morbidity, mortality, and costs.5 The high proportion of reoperations has
generated controversy about the optimum approach for fixing femoral neck fractures.6
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Biomechanical and laboratory studies7 suggest that although a single large screw at a fixed
angle with a side-plate (ie, a sliding hip screw) provides greater biomechanical stability,
especially in displaced and unstable fracture types, multiple cancellous screws, which is the
present standard of care, are less invasive and better preserve blood supply. Previous small
trials6 did not find a difference in the effect of the two fixation approaches on outcomes
important to patients, particularly reoperations, leaving uncertainty among surgeons about
the optimum approach for fixing femoral neck fractures.
We did the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH)
trial to examine the effect of a sliding hip screw versus cancellous screws on the risk of
reoperation and other key outcomes during 24 months.

Methods
Study design and participants
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FAITH was an international, multicentre, allocation concealed, randomised controlled trial
assessing the effects of a sliding hip screw versus cancellous screws on reoperation rates
over a 24 month follow-up in patients with a low-energy femoral neck fracture. A previous
report8 details the trial objectives and methods. All participating centres obtained ethics
approval.
We enrolled patients with a low-energy fracture of the hip requiring fracture fixation across
81 clinical centres in the USA, Canada, Australia, the Netherlands, Norway, Germany, the
UK, and India. Eligible patients were those aged 50 years or older with a low-energy
femoral neck fracture requiring operative fixation. Complete eligibility criteria are provided
in the appendix. All patients provided written informed consent.
Randomisation and masking
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Patients were randomly assigned by minimisation to receive a sliding hip screw or
cancellous screws, with a centralised computer system to ensure allocation concealment and
balanced prognosis between intervention groups for fracture displacement, age, prefracture
living status, prefracture function, American Society for Anesthesiologists class, and centre.
9 The study computer programmer generated the minimisation algorithm. Local research
personnel at each site performed randomisation by minimisation using the centralised
computer system. Surgeons and patients were not masked but the data analyst, while doing
the analyses, remained masked to treatment groups.
Procedures
Participants allocated to the sliding hip screw group received a single large-diameter (8.0
mm), partly threaded screw affixed to the proximal femur with a side plate (with a minimum
of two holes and a maximum of four holes) and no supplemental fixation. Patients allocated
to the cancellous screws group received multiple threaded screws, with a minimum of two
screws and diameter of 6.5 mm. All participating surgeons had done at least 25 hip fracture
fixation procedures during their career, and at least five fracture fixation procedures in the
year before participation.
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Surgeons chose the manufacturer, the reduction technique, whether to do a capsulotomy or
aspiration of intracapsular haematoma, and the final screw position; injectable bone
substitutes were not permitted. The protocol specified perioperative antibiotics, thromboprophylaxis, and weight-bearing regimens, but left to the surgeons’ discretion patient
positioning, fracture reduction, and surgical exposure in the operating room. We provided
surgeons with specific criteria for acceptability of postfixation radiographic fracture
alignment.
Participants returned for follow-up at 1 and 10 weeks, and at 6, 9, 12, 18, and 24 months
after surgery. Additional details of the trial intervention and standardisation of perioperative
care, surgeon expertise, and the follow-up processes are provided in the appendix.
Outcomes
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The primary endpoint was reoperation, defined as surgery that occurred subsequent to the
initial procedure and within 24 months to promote fracture healing, relieve pain, treat
infection, or improve function. An independent Central Adjudication Committee,
adjudicated all primary and key secondary outcomes (mortality, fracture healing, and
fracture complications, including avascular necrosis, non-union, implant failure, and
infections). Health-related quality of life was measured by the Short Form-12, the EuroQol-5
Dimensions, and the Western Ontario and McMaster Universities Arthritis Index. Details of
the primary outcomes, secondary outcomes, and adjudication processes are provided in the
appendix.
All adverse events were reported to local ethics boards as per local requirements. An
independent Data and Safety Monitoring Board monitored the safety of the trial and
reviewed all serious adverse events.
Statistical analysis
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The sample size calculation was based on the primary outcome of hip reoperation and used
the Cox proportional hazards model as described by Collett.10 Originally we determined that
enrolment of 1500 patients would give the trial 81.5% power to detect a hazard ratio (HR) of
0.75 in the sliding hip screw group, at a two-sided alpha level of 0.05, on the assumption that
the percentage of the primary outcome in the cancellous screws group would be 25%
(appendix).8
The Data and Safety Monitoring Board met in January, 2014, after 589 patients completed
follow-up. They provided the Steering Committee with overall event rates to inform a
revised power analysis that balanced feasibility of completing recruitment within an
acceptable timeframe and supporting plausible hypotheses of treatment effect and baseline
event rates. On the basis of the number of events in the first 589 patients, we estimated a 24
month primary event rate of 27.2%; a 24 month mortality rate of 18.2%; a 24 month 5.9%
incidence of loss to follow-up; and a combined 6.8% crossover rate. With these estimates, a
sample size of 500 patients per group would provide 95.7% power to detect a relative risk
reduction of 35%. On the basis of these data, we targeted a sample size of 1100 patients. A
methods paper8 published previously presents details of the sample size calculations and
rationale.
Lancet. Author manuscript; available in PMC 2017 September 13.
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Analyses followed the intention-to-treat principle and included all patients in the groups to
which they were randomly assigned. Patients who did not complete the 24 month follow-up
were censored at their last documented follow-up. After assessment of its appropriateness,
the primary analysis used a Cox proportional hazards model stratified by clinical site. We
report the treatment effects as HRs and 95% CIs. An analysis adjusting for death as a
competing risk provided a sensitivity analysis. The analyses of treatment effect on fracturerelated adverse events and mortality also relied on a stratified Cox proportional hazards
regression.
We analysed the health-related quality-of-life outcomes at 24 months using a multiple linear
regression model with treatment and pre-injury quality of life (obtained at 1 week) included
as independent variables. Results are reported as mean differences with corresponding 95%
CIs and p values.
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At the trial onset we specified a single a-priori subgroup analysis investigating fracture
displacement as a possible effect modifier, anticipating that sliding hip screw relative to
multiple cancellous screws would do better in displaced versus non-displaced fractures.10 At
the completion of the trial, but before unblinding and as described in our statistical analysis
plan, we prespecified an additional five subgroup analyses that investigated a possible effect
modification by location of fracture line, body-mass index, verticality of the fracture line,
smoking status, and quality of fracture reduction. We did an additional post-hoc subgroup
analysis assessing the possible effect modification of patient age. We did tests of interaction
for individual subgroups and, when three provide significant results, an analysis that
simultaneously considered all their possible interactions. We used multiple criteria to
consider the credibility of any possible subgroup effects.11,12 Details for postulated
subgroup effects are provided in the appendix. All analyses were done with SAS version 9.4
(Cary, NC, USA). This study was registered with ClinicalTrials.gov, number NCT00761813.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all the
data in the study and had final responsibility for the decision to submit for publication.
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Results
Between March 3, 2008, and March 31, 2014, we randomly assigned 1108 patients to
receive a sliding hip screw (n=557) or cancellous screws (n=551; figure 1). The
Adjudication Committee determined that 29 patients were ineligible, most as a result of an
ineligible fracture type, or surgical treatment delayed beyond 4 days in patients with
displaced fractures, leaving 1079 patients in the final analyses. The rationale for postrandomisation exclusions is in the appendix. Of the 923 patients alive at 24 months, we
achieved 24 month follow-up for 844 (91%; figure 1, appendix). The mean length of followup was 633 days (SD 208).
Typical patients were women aged 70–80 years who had fallen and sustained an isolated,
non-displaced fracture of the femoral neck; group characteristics were similar (tables 1, 2).
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Acceptable reduction (open and closed) was achieved in nearly all patients (99%; table 2). In
549 patients with displaced fractures, acceptable reduction was achieved in 545 (99%).
Those who underwent cancellous screw fixation typically received three parallel screws in a
triangular configuration, whereas those in the sliding hip screw group received a single large
compression screw in the centre–centre head position with a two-hole side plate;
perioperative management was similar across groups (tables 1, 2; appendix).
The overall crossover was 2.0%, with significant differential crossovers between treatment
groups (p=0.03). Surgeon compliance for the initial allocated surgical fixation approach was
97% (n=16) for sliding hip screw and 99% (n=6) for cancellous screws (appendix).
The primary study endpoint, hip reoperation within 24 months, did not differ by type of
surgical fixation (table 3, figure 2). A competing risk sensitivity analysis adjusting for death
yielded similar results for the primary endpoint (0.89, 0.69–1.16).
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Number of deaths did not differ between groups (table 3). Avascular necrosis occurred in
about 7% of patients overall and differed by fixation group, with more occurring in the
sliding hip screw group than in the cancellous screws group. Of these, 54 (69%) patients
required an operation: 38 patients in the sliding hip screw group and 16 in the cancellous
screws group (p=0.002). Implant removal took place significantly less frequently in the
sliding hip screw group than in the cancellous screws group (table 3). Implant exchange to
revise to another internal fixation also occurred less frequently with sliding hip screws than
cancellous screws (table 3). Alternatively, implant exchange to a total hip replacement was
more common in the sliding hip group.
Non-unions, implant failures, infections, fracture shortening, and fracture healing did not
differ by surgical fixation approach (table 3). Health-related quality of life did not differ
between patients assigned to sliding hip screws and multiple cancellous screws at 12 month
and 24 month follow-up (table 4).
Medically related adverse events did not differ by treatment group (p=0.82; table 5).
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Subgroup analyses favoured sliding hip screw in patients with displaced fractures, fractures
at the base of the femoral neck, and in those who were current smokers (appendix, figure 3).
Only smoking status remained significant when these three subgroups were entered into a
single analysis (figure 3). Sliding hip screw was superior in current smokers, but not in
former or non-smokers (figure 3, appendix).

Discussion
We have shown a similar risk of hip reoperation in patients with low-energy femoral neck
fractures randomly assigned to sliding hip screw as in those assigned to cancellous screws at
24 months; avascular necrosis occurred more frequently in patients allocated to sliding hip
screw. Subgroup analyses of low-to-moderate credibility, suggested sliding hip screws
reduced reoperations in patients with displaced fractures, fractures at the base of the femoral
neck, and in current smokers.
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Although the frequency of reoperations was similar between the two treatment groups, there
were differences in the component outcomes of reoperations. Patients in the sliding hip
screw group, compared with those in the cancellous screws group, had a lower frequency of
a reoperation for an implant removal and an implant exchange based on an internal fixation
approach, but had a higher frequency of reoperation for an implant exchange with a total hip
arthroplasty approach. Patients undergoing total hip arthroplasty after failed internal fixation
compared with those undergoing primary total hip arthroplasty could be at higher risk of
complications.19 As such, the number of arthroplasties in the cancellous screws group
suggests a potential advantage of the treatment over a sliding hip screw. Although the
decision to choose one approach to implant exchange over another was left to the surgeon’s
discretion, the choice might also indicate surgeon preference.
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Looking separately at possible effect modifiers, displaced versus non-displaced fractures,
fracture site, and smoking status, interaction p values all reached conventional statistical
significance, all suggesting benefits of sliding hip screws over cancellous screws in a
subpopulation of patients (figure 3). All were a-priori hypotheses with a biological rationale
that led to a correct predicted direction of effect. In particular, the greater biomechanical
stability of sliding hip screws might offer advantages in fracture with displacement and in
smokers, who have greater risk of osteoporosis and diminished bone density than do nonsmokers.7,20–23 Sliding hip screws remain the standard of care in patients with intertrochanteric fractures, a region in close proximity to the base of the femoral neck,24
providing a biological rationale for the finding that sliding hip screws reduced reoperations
in the subgroup of patients with base of femoral neck fractures. Furthermore, the
displacement hypothesis was originally our sole hypothesis and a minimisation variable.11,12
However, when all three potential effect modifiers were considered together, only smoking
retained a low, although not extremely low, p value (figure 3). Additionally, we tested
multiple hypotheses, and did not find similar effects in health-related quality of life. As such,
in view of all these issues, the apparent subgroup effects have only modest credibility.
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Strengths of FAITH include safeguards against risk of bias (concealed randomisation,
centralised and independent outcome adjudication, blinded analysis of data); high
compliance with study procedures; broad inclusion criteria with a large number of centres in
countries with diverse health-care systems; a focus on outcomes of importance to both
patients and the health-care system (ie, reoperation, health-related quality of life); and
rigorous investigation of subgroup effects, with due attention to their credibility.11,12
Our study has limitations. Surgeons and patients were not blinded. However, we did
minimise the associated risk of bias with central and independent, although unblinded,
radiographic adjudication of the primary endpoint. Furthermore, reoperation is an objective
endpoint and a major procedure; surgeons will seldom decide to reoperate in the absence of
a compelling indication. Follow-up at 24 months was less than complete (844 [91%] of 923
patients who were alive); our success in following up patients was consistent and in most
cases better than in previous smaller trials.3 Unavoidable heterogeneity related to the
variables that were not standardised also existed; these variables were patient positioning,
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fracture reduction, surgical exposure, use of operative traction, surgical delay, type of
anaesthetic, physiotherapy, and rehabilitation programmes.
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In relation to previous research, a meta-analysis of small trials suggested a non-significant
difference in reoperations favouring sliding hip screw (relative risk 0.86, 95% CI 0.70–1.05;
p=0.13).19 An updated pooled analysis of reoperation including small trials with our FAITH
results (eight trials, 1913 patients) reported a 95% CI that was narrower than our study’s but
was still consistent, with no difference between fixation methods (0.91, 0.76–1.08; p=0.27,
I2=7%).25–31
With respect to avascular necrosis, our results differ importantly from a previous systematic
review19 of small trials, which suggested that a sliding hip screw, in comparison with
cancellous screws, might reduce the risk of avascular necrosis. The addition of another small
trial to a previous meta-analysis results in a significant reduction in the risk of avascular
necrosis with sliding hip screws (77 events; relative risk 0.64, 95% CI 0.43–0.97; p=0.04,
I2=0%).19,25
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Despite the previous results, increased risk of avascular necrosis from our results has a
plausible biological rationale. Hip fractures can disrupt the retinacular vessels, which are
crucial for the vascular supply of the femoral head.32 A randomised trial33 of 104 patients
with femoral neck fractures using bone scintigraphy showed reduced vascularity in patients
receiving a sliding hip screw compared with those receiving cancellous screws (35% vs
11%, p<0.01). Furthermore, suboptimum positioning of large implants, such as sliding hip
screws, risks damage to the blood supply to the femoral head.34 In terms of the importance
of avascular necrosis, observational studies have shown that many patients remain
asymptomatic, with only one in five requiring further surgery.35,36
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Our results, in the context of previous results, suggest that the choice of procedure for
internal fixation is a matter of discretion. Findings favouring cancellous screws were the
non-significant difference in the likelihood of reoperation between procedures, and the
higher likelihood of avascular necrosis and subsequent total arthroplasties in patients
receiving a sliding hip screw. However, our finding of increased avascular necrosis with a
sliding hip screw, compared with cancellous screws, is inconsistent with other studies and
did not result in more operations or poorer quality of life in the total population. Moreover,
findings across all trials remain consistent, with overall decreased reoperations in patients
receiving a sliding hip screw, and subgroup analyses of low credibility suggesting that
patients with displaced fractures, smokers, and patients with base of neck fractures might do
better with a sliding screw than with cancellous screws.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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We searched the computerised databases Medline and PubMed for randomised clinical
trials published in English between Jan 1, 1969, and June 1, 2002, using the search terms
“femoral neck fracture” AND “arthroplasty”, as well as “femoral neck fracture” AND
“internal fixation”. In addition, bibliographies were searched for relevant studies. We also
identified additional studies through hand searches of major orthopaedic journals,
bibliographies of major orthopaedic textbooks, and personal files. Of 140 citations
initially identified, 14 met all eligibility criteria. Three investigators independently graded
study quality and abstracted relevant data, including information on revision and
mortality rates. An international survey of orthopaedic surgeons identified that most
surgeons preferred to fix femoral neck hip fractures with multiple cancellous screws
rather than a sliding hip screw. Despite the popularity of cancellous screws for hip
fracture fixation, biological investigations have suggested that the sliding hip screw is a
more biomechanically stable construct compared with cancellous screws. Moreover, a
previous Cochrane meta-analysis of small trials reported a non-significant reduction in
reoperations with a sliding hip screw compared with multiple cancellous screws (relative
risk 0.86, 95% CI 0.70–1.05), and that the risk of avascular necrosis with a sliding hip
screw was significantly reduced. The small sample sizes and resultant imprecise
estimates, and methodological limitations, of previous work left the issue in doubt.
Added value of this study
Our trial enrolled more than 1000 patients across multiple countries, providing improved
precision and generalisability to both high-income countries and low-to-middle-income
countries. Our trial also addresses the dearth of health-related quality-of-life data for
patients who had surgical fixation for femoral neck fractures.
Implications of all the available evidence
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Although our findings, consistent with those of previous randomised controlled trials, did
not show a difference in the likelihood of reoperation in patients randomly assigned to a
sliding hip screw versus cancellous screws, health-related quality of life was similar
across both interventions. However, we did show a significant increase in the likelihood
of avascular necrosis with a sliding hip screw compared with cancellous screws.
Nonetheless, this finding is not only inconsistent with previous results, but also did not
result in an overall increase in reoperations or a decrement in health-related quality of
life. Moreover, our results raise the possibility that a sliding hip screw, relative to
cancellous screws, might reduce reoperations in patients with displaced fractures, in
smokers, and in patients with base of neck fractures.
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Figure 1.

Trial profile
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Figure 2.

Kaplan-Meier curves for reoperation

CIHR Author Manuscript
CIHR Author Manuscript
Lancet. Author manuscript; available in PMC 2017 September 13.

Page 14

CIHR Author Manuscript
CIHR Author Manuscript

Figure 3. Subgroup analyses of surgical fixation primary endpoint (reoperation)

BMI=body-mass index.*Interaction p value for group comparison. †Defined at study start.
‡Defined at study close (before unblinding).
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Baseline characteristics
Sliding hip screw (n=542)

Cancellous screws (n=537)

Total (n=1079)

72.2 (12.0)

72.0 (12.3)

72.1 (12.2)

Male

212/535 (40%)

210/535 (39%)

422/1070 (39%)

Female

323/535 (60%)

325/535 (61%)

648/1070 (61%)

Age (years)
Sex

Ethnic origin
Native

1/533 (<1%)

3/535 (1%)

4/1068 (<1%)

South Asian

65/533 (12%)

65/535 (12%)

130/1068 (12%)

East Asian

6/533 (1%)

4/535 (1%)

10/1068 (1%)

Black

22/533 (4%)

18/535 (3%)

40/1068 (4%)

Hispanic

3/533 (1%)

1/535 (<1%)

4/1068 (<1%)

436/533 (82%)

444/535 (83%)

880/1068 (82%)

Never smoked

268/533 (50%)

276/532 (52%)

544/1065 (51%)

Current smoker

101/533 (19%)

100/532 (19%)

201/1065 (19%)

Former smoker

164/533 (31%)

156/532 (29%)

320/1065 (30%)

None

170/535 (32%)

179/534 (34%)

349/1069 (33%)

NSAIDS

86/535 (16%)

64/534 (12%)

150/1069 (14%)

General cardiac

167/535 (31%)

167/534 (31%)

334/1069 (31%)

43/535 (8%)

56/534 (10%)

99/1069 (9%)

White
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Smoking history

Current drugs

Opioid analgesics
Pulmonary drugs

58/535 (11%)

69/534 (13%)

127/1069 (12%)

Anti-hypertension drugs

244/535 (46%)

252/534 (47%)

496/1069 (46%)

Osteoporosis drugs

67/535 (13%)

73/534 (14%)

140/1069 (13%)

BMI
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Underweight (BMI <18.5)

37/530 (7%)

33/528 (6%)

70/1058 (7%)

Normal weight (18.5–24.9)

276/530 (52%)

300/528 (57%)

576/1058 (54%)

Overweight (25–29.9)

159/530 (30%)

148/528 (28%)

307/1058 (29%)

Obese (30–39.9)

58/530 (11%)

47/528 (9%)

105/1058 (10%)

N=535

N=535

N=1070

Left

280/535 (52%)

281/535 (53%)

561/1070 (52%)

Right

255/535 (48%)

254/535 (47%)

509/1070 (48%)

515/533 (97%)

521/534 (98%)

1036/1067 (97%)

Spontaneous

13/533 (2%)

6/534 (1%)

19/1067 (2%)

Other low energy trauma

5/533 (1%)

7/534 (1%)

12/1067 (1%)

Fractured hip

Mechanism of injury
Fall
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Sliding hip screw (n=542)

Cancellous screws (n=537)

Total (n=1079)

History of surgery to affected hip
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Yes

3/535 (1%)

0/535 (0%)

3/1070 (<1%)

No

532/535 (99%)

535/535 (100%)

1067/1070 (100%)

Additional injuries
Yes

67/535 (13%)

72/535 (13%)

139/1070 (13%)

No

468/535 (87%)

463/535 (87%)

931/1070 (87%)

Data are mean (SD) or n/N (%). For some subgroups, the numbers of patients analysed are smaller than that of the overall group number because
data are missing for some variables. NSAIDS=non-steroidal anti-inflammatory drugs. BMI=body-mass index.
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Fracture characteristics
Sliding hip screw (n=542)

Cancellous screws (n=537)

Total (n=1079)

Level of the fracture line
Subcapital

331/535 (62%)

351/536 (65%)

682/1071 (64%)

Midcervical

159/535 (30%)

154/536 (29%)

313/1071 (29%)

Basal

45/535 (8%)

31/536 (6%)

76/1071 (7%)

Garden classification13
Undisplaced

360/542 (66%)

369/537 (69%)

729/1079 (68%)

Garden I

257/542 (47%)

277/537 (52%)

534/1079 (49%)

Garden II

99/542 (18%)

92/537 (17%)

191/1079 (18%)

182/542 (34%)

168/537 (31%)

350/1079 (32%)

Garden III

121/542 (22%)

128/537 (24%)

249/1079 (23%)

Garden IV

58/542 (11%)

39/537 (7%)

97/1079 (9%)

Displaced
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Pauwel’s classification14,15
Type I

59/535 (11%)

59/536 (11%)

118/1071 (11%)

Type II

398/535 (74%)

394/536 (74%)

792/1071 (74%)

Type III

78/535 (15%)

83/536 (15%)

161/1071 (15%)

Preoperative traction
Skin traction

75/535 (14%)

76/535 (14%)

151/1070 (14%)

Skeletal traction

7/535 (1%)

3/535 (1%)

10/1070 (1%)

None

453/535 (85%)

456/535 (85%)

909/1070 (85%)

None

210/531 (40%)

237/528 (45%)

447/1059 (42%)

Closed

287/531 (54%)

277/528 (52%)

564/1059 (53%)

Acceptable

286/287 (100%)

275/277 (99%)

561/564 (99%)

Unacceptable

1/287 (<1%)

2/277 (1%)

3/564 (1%)

Type of reduction
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Open

34/531 (6%)

14/528 (3%)

48/1059 (5%)

Acceptable

32/34 (94%)

14/14 (100%)

46/48 (96%)

Unacceptable

2/34 (6%)

0/14 (0%)

2/48 (4%)

Data are n/N (%).
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Study outcomes by treatment group
Overall (n=1079)

Sliding hip
screw (n=542)

Cancellous screws (n=537)

Hazard ratio
(95% CI)

p value

224 (21%)

107 (20%)

117 (22%)

0.83 (0.63–1.09)

0.18

74 (7%)
104 (10%)

25 (5%)

49 (9%)

0.42 (0.25–0.70)

0.0009

64 (12%)

40 (7%)

1.51 (1.00–2.27)

0.0494

Reoperation
Any reoperation
Implant removal
Implant exchange: total hip
arthroplasty
Implant exchange: hemiarthroplasty

55 (5%)

26 (5%)

29 (5%)

0.89 (0.52–1.51)

0.66

Implant exchange: internal

16 (1%)

2 (<1%)

14 (3%)

0.14 (0.03–0.62)

0.0024

3 (<1%)

1 (<1%)

2 (<1%)

0.50 (0.05–5.45)

0.56

Fixation
Implant exchange: spacer
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Soft tissue procedure

6 (1%)

4 (1%)

2 (<1%)

1.98 (0.36–10.77)

0.42

Proximal femoral osteotomy

1 (<1%)

1 (<1%)

1 (<1%)

0.99 (0.06–15.80)

0.99

Avascular necrosis

78 (7%)

50 (9%)

28 (5%)

1.91 (1.06–3.44)

0.0319

Non-union

66 (6%)

33 (6%)

33 (6%)

0.92 (0.48–1.75)

0.80

Implant failure

87 (8%)

42 (8%)

45 (8%)

0.95 (0.61–1.48)

0.81

Any infection

19 (2%)

10 (2%)

9 (2%)

1.10 (0.45–2.69)

0.83

Superficial infection

8 (1%)

4 (1%)

4 (1%)

0.99 (0.25–3.94)

0.99

Deep infection

11 (1%)

6 (1%)

5 (1%)

1.19 (0.37–3.87)

0.77

532/795 (67%)

262/398 (66%)

270/397 (68%)

..

0.71

3/795 (<1%)

2/398 (1%)

1/397 (<1%)

..

260/795 (33%)

134/398 (34%)

126/397 (32%)

..

146/532 (27%)

69/262 (26%)

77/270 (29%)

0.92 (0.70–1.22)

0.57

156 (14%)

73 (13%)

83 (15%)

0.81 (0.58–1.12)

0.20

Infection

Fracture healing*
Healed by month 24
Not healed by month 24
Not healed at time of last visit
Fracture shortening >5 mm (n=532)†
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Mortality

Data are n (%). Relative risk was calculated where the total number of events is less than 50.

*

795 patients were included in the fracture healing analysis. 284 patients did not have radiograph available for fracture healing adjudication, and
therefore were not included in the denominator.

†

532 patients were included in the shortening analysis on the basis of the number of healed fractures with shortening data.
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Health-related quality of life by treatment groups without interaction of displacement
Sliding hip screw

Cancellous screws

n

Adjusted mean difference (95% CI)

p value for differences
between groups

n

Mean (SD)

n

Mean (SD)

SF-12 PCS16

235

40.8 (11.1)

224

41.9 (10.7)

435

−0.02 (−1.79 to 1.74)

0.98

WOMAC17

240

44.69 (19.08)

226

41.32 (16.73)

438

1.98 (−1.13 to 5.09)

0.21

249

0.77 (0.20)

238

0.80 (0.17)

460

−0.02 (−0.05 to 0.02)

0.33

SF-12 PCS16

207

41.6 (10.9)

181

41.4 (11.8)

358

0.50 (−1.61 to 2.61)

0.64

WOMAC17

205

40.97 (16.33)

183

39.75 (17.09)

355

0.35 (−3.03 to 3.74)

0.84

232

0.79 (0.19)

207

0.80 (0.19)

406

−0.01 (−0.04 to 0.02)

0.51

12 months

EQ-5D

Index18

24 months

EQ-5D

Index18

CIHR Author Manuscript

SF-12 PCS=Short Form-12. PCS=Physical component score. WOMAC=Western Ontario and McMaster Universities Arthritis Index.
EQ-5D=EuroQol-5 Dimensions.
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Medically related adverse events
Sliding hip screw (n=542)

Cancellous screws (n=537)

p value

23 (4%)

24 (4%)

0.86

Deep vein thrombosis

6 (1%)

8 (1%)

0.58

Pulmonary embolism

2 (<1%)

4 (1%)

0.41

Sepsis

7 (1%)

6 (1%)

0.79

Myocardial infarction

9 (2%)

7 (1%)

0.63

Pneumonia
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Congestive heart failure

7 (1%)

6 (1%)

0.79

Other cardiovascular adverse events

43 (8%)

43 (8%)

0.96

Pulmonary

24 (4%)

16 (3%)

0.21

Decreased cognitive ability

14 (3%)

23 (4%)

0.12

Neurological

10 (2%)

10 (2%)

0.98

Digestive

17 (3%)

18 (3%)

0.84

Blood

17 (3%)

12 (2%)

0.36

Renal

8 (1%)

10 (2%)

0.62

Urinary

23 (4%)

20 (4%)

0.66

Multiple organ complications

3 (1%)

0

0.08

122 (23%)

124 (23%)

0.82

Total
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